Adamas to Present at the 37th Annual Cowen Health Care Conference
01 mars 2017 14h43 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas, is...
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2016
28 févr. 2017 16h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year...
Adamas Presents Additional Open-Label, Long-Term Safety and Efficacy Data on ADS-5102 at the First Pan American Parkinson’s Disease and Movement Disorders Congress
28 févr. 2017 08h30 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of additional data from EASE LID 2, its Phase 3 open-label,...
Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements
08 janv. 2017 19h57 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today outlines key business priorities for 2017, in addition to providing a review of 2016...
Adamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease
06 janv. 2017 09h00 HE
|
Adamas Pharmaceuticals, Inc.
-- PDUFA Action Date Set for August 24, 2017 -- -- If Approved, ADS-5102 will be the First and Only Medicine Approved for the Treatment of LID in Parkinson’s Disease -- EMERYVILLE, Calif.,...